Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
methyl Also carbinyl. The alkyl functional group derived from methane, consisting of one carbon atom bonded to three hydrogen atoms, with the chemical formula CH3. It is the simplest hydrocarbon and occurs as a substituent in numerous organic compounds, though it may also exist independently as an ion or radical. In IUPAC nomenclature, the presence of a methyl substituent is indicated with the prefix methyl in the name of the compound, or with the abbreviation Me in chemical formulae; e.g. methyl alcohol (methanol) is often written with the formula CH3OH or MeOH.
=== August === 3 August – Researchers propose a theoretical method using quantum lattice gates to perform operations on bosonic quantum error-correcting codes within a single driving cycle, potentially making some operations more than 1,000 times faster than previous approaches and advancing efforts towards fault-tolerant quantum computing. 5 August – A study published in the JAMA Network Open shows that the fecal immunochemical test (FIT) has reduced deaths from colorectal cancer. 13 August – A meta-analysis of more than 480,000 participants finds that regular stair climbing is associated with a 39% lower risk of cardiovascular mortality and a 24% lower risk of death from any cause. 17 August A team of researchers combine synthetic DNA and a semiconductor to produce an ultra-low-power memory device – one that can carry out both the storage and processing of information within a single, unified location. This cutting-edge, bio-hybrid technology may in time contribute to far greater energy efficiency across AI systems and next-generation computers alike. Researchers at the Max Planck Institute for Marine Microbiology find that dozens of animal species carry enzymes capable of breaking down microbe-derived bioplastics known as PHAs, a long-standing talent once believed to belong exclusively to microorganisms.
== Operations == JEOL Ltd. has four business segments. Electron Optics manufactures scanning electron microscopes, transmission electron microscopes and scanning probe microscopes, along with related equipment. The Analytical Instruments section's products include mass spectrometers, nuclear magnetic resonance and electron spin resonance equipment. The Industrial Equipment segment covers a range of equipment particularly targeted at the semiconductor industry, such as electron beam sources, wafer process monitors, and plasma gun series. Finally, the Medical Equipment segment manufactures automatic analysis devices, clinical diagnostic systems and amino acid analyzers.
The grant proposal was turned over for peer review, and one of the reviewers was Steven Jones of Brigham Young University. Jones had worked for some time on muon-catalyzed fusion, a known method of inducing nuclear fusion without high temperatures, and had written an article on the topic entitled "Cold nuclear fusion" that had been published in Scientific American in July 1987. Fleischmann and Pons and co-workers met with Jones and co-workers on occasion in Utah to share research and techniques. During this time, Fleischmann and Pons described their experiments as generating considerable "excess energy", in the sense that it could not be explained by chemical reactions alone. They felt that such a discovery could bear significant commercial value and would be entitled to patent protection. Jones, however, was measuring neutron flux, which was not of commercial interest. To avoid future problems, the teams appeared to agree to publish their results simultaneously, though their accounts of their 6 March meeting differ.
Sources: en.wikipedia.org
Microwave relay – a long-distance high bandwidth point-to-point digital data transmission link consisting of a microwave transmitter connected to a dish antenna that transmits a beam of microwaves to another dish antenna and receiver. Since the antennas must be in line-of-sight, distances are limited by the visual horizon to 30–40 miles (48–64 km). Microwave links are used for private business data, wide area computer networks (WANs), and by telephone companies to transmit long-distance phone calls and television signals between cities. Telemetry – automated one-way (simplex) transmission of measurements and operation data from a remote process or device to a receiver for monitoring. Telemetry is used for in-flight monitoring of missiles, drones, satellites, and weather balloon radiosondes, sending scientific data back to Earth from interplanetary spacecraft, communicating with electronic biomedical sensors implanted in the human body, and well logging. Multiple channels of data are often transmitted using frequency-division multiplexing or time-division multiplexing. Telemetry is starting to be used in consumer applications such as: Automated meter reading – electric power meters, water meters, and gas meters that, when triggered by an interrogation signal, transmit their readings by radio to a utility reader vehicle at the curb, to eliminate the need for an employee to go on the customer's property to manually read the meter.
Under the 1999 constitution and a 2009 constitutional amendment, the president of Venezuela is elected for a six-year term by direct popular vote and may be re-elected indefinitely. Nicolás Maduro, the outgoing Venezuelan president who was reelected to a disputed third term in 2024, was captured in Venezuela by the United States Armed Forces during a large-scale military operation and extradited to New York to face narcotics-related charges, triggering a major political and constitutional crisis. Vice-president Delcy Rodríguez was installed as acting president by Venezuela's Supreme Tribunal of Justice (TSJ), which described Maduro's situation as a "temporary absence", leaving the timing of the next presidential election unclear.
Barbara Seliger Larsen is a mass spectrometrist, with a career in instrumentations and applications of mass spectrometry in industry, and served on the board of the American Society for Mass Spectrometry for several terms.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.